KIR/KIR 配体基因型与接受 BEMPEG 联合 nivolumab 治疗的晚期实体瘤患者临床结局之间的关联：PIVOT-02 试验

Bempegaldesleukin (BEMPEG), a CD122-preferential IL2 pathway agonist, has been shown to induce proliferation and activation of NK cells. NK activation is dependent on the balance of inhibitory and excitatory signals transmitted by NK receptors, including Fc-gamma receptors (FCγRs) and killer immunoglobulin-like receptors (KIRs) along with their KIR-ligands. The repertoire of KIRs/KIR-ligands an individual inherits and the single-nucleotide polymorphisms (SNPs) of FCγRs can influence NK function and affect responses to immunotherapies.

In this retrospective analysis of the single-arm PIVOT-02 trial, 200 patients with advanced solid tumors were genotyped for KIR/KIR-ligand gene status and FCγR SNP status and evaluated for associations with clinical outcome. Patients with inhibitory KIR2DL2 and its ligand (HLA-C1) observed significantly greater tumor shrinkage (TS, median change -13. 0 vs. 0%) and increased PFS (5. 5 vs. 3. 3 months) and a trend toward improved OR (31. 2 vs. 19. 5%) compared to patients with the complementary genotype.

Furthermore, patients with KIR2DL2 and its ligand together with inhibitory KIR3DL1 and its ligand (HLA-Bw4) had improved OR (36. 5 vs. 19. 6%), greater TS (median change -16. 1 vs. 0%), and a trend toward prolonged PFS (8. 4 vs. 3. 6 months) as compared to patients with the complementary genotype. FCγR polymorphisms did not influence OR/PFS/TS. These data show that clinical response to BEMPEG plus nivolumab treatment in the PIVOT-02 trial may be associated with the repertoire of KIR/KIR-ligands an individual inherits.

Further investigation and validation of these results may enable KIR/KIR-ligand genotyping to be utilized prospectively for identifying patients likely to benefit from certain cancer immunotherapy regimens.